COMP <GO>
BTMD vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Biote Corp. (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BTMD 3
— LLY 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: BTMD
LAST: $1.17 (+1.74%) • MKT CAP: $42.0M
roic
85.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BTMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BTMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 85.00% | 32.36% | +52.64 | BTMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 2.9x | 36.4x | -33.52 | BTMD | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 18.50% | 40.21% | -21.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 14.10% | 31.90% | -17.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -2.50% | 45.51% | -48.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.11% | 0.49% | +3.62 | BTMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 9.29 | -6.79 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 66.6 | -17.10 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.0M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BTMD REV | LLY REV | BTMD GROSS % | LLY GROSS % | BTMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $192.2M | $65.18B | — | 83.0% | $30.2M | $16.81B |
| FY 2024 | $197.2M | $45.04B | — | 81.3% | $38.8M | $8.82B |
| FY 2023 | $185.4M | $34.12B | — | 79.3% | $26.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BTMD // BETA —
LLY // BETA 0.51